Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl 4-deoxy-4-fluoro-D-glucopyranoside is a synthetic, fluorinated methyl-glycoside that serves as a high-affinity, selective substrate for the **Sodium/glucose cotransporter 1 (SGLT1)** and, to a lesser extent, **Sodium/glucose cotransporter 2 (SGLT2)**. Unlike glucose, which is transported by both SGLTs and facilitated diffusion (GLUT) transporters, this compound is specifically recognized by active transport systems and exhibits negligible affinity for GLUT transporters such as GLUT1 and GLUT2. This high selectivity makes it an invaluable diagnostic tool and molecular probe for studying active sugar transport in physiological systems, particularly in the small intestine and kidneys. When synthesized using the radioactive isotope fluorine-18 ([18F]Me-4FDG), it is utilized in **Positron Emission Tomography (PET)** imaging to non-invasively quantify SGLT expression and activity. The development of this agent as a clinical imaging probe has been primarily led by researchers at the **University of California, Los Angeles (UCLA)**, with applications targeting oncology—where SGLT proteins are often overexpressed—and metabolic research involving diabetes mellitus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl 4-deoxy-4-fluoro-D-glucopyranoside.